AN2 Therapeutics (ANTX) vs Cue Biopharma (CUE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed Cue Biopharma (CUE) over the past year, gaining 262.8% versus a loss of 0.4%. Cue Biopharma is the larger company by market cap ($200.9 million vs $166.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANTX | CUE |
|---|---|---|
| Share price | $4.40 | $27.66 |
| Market cap | $166.04M | $200.93M |
| 1-day change | -5.98% | +23.87% |
| YTD return | +310.53% | +202.30% |
| 1-year return | +262.79% | -0.43% |
| 5-year return | — | -92.68% |
| EPS (TTM) | $-1.05 | $-29.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.19 | $45.50 |
| 52-week low | $1.00 | $4.98 |
| Distance from 52-week high | -38.80% | -39.21% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +104.55% | +218.15% |
| Average volume | 240.21K | 267.15K |
| Shares outstanding | 37.74M | 7.26M |
| Employees | 21 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed CUE by 263.2 percentage points over the past year.
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
ANTX vs CUE FAQ
Which is bigger, AN2 Therapeutics or Cue Biopharma?
Cue Biopharma (CUE) is larger, with a market capitalization of $200.93M compared with $166.04M for AN2 Therapeutics (ANTX).
Which stock has performed better over the past year, ANTX or CUE?
ANTX returned +262.79% over the past 12 months, compared with -0.43% for CUE (price return, excluding dividends). Past performance does not predict future results.
Are AN2 Therapeutics and Cue Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.